OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. OriGene's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research.
OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. In August 2010, OriGene acquired Blue Heron Biotech and now offers complete molecular biology services from codon optimization, gene synthesis, protein expression and assay development. In 2013, OriGene acquired the assets of the Life Science business of SDIX, a leading provider of biological products and services.
OriGene has made tremendous efforts in developing the most specific antibodies -- UltraMABs -- for anatomic pathology and other diagnostic purposes. A novel technology called "High-density Protein Microarray" was developed to validate the specificity of each UltraMAB. In addition to UltraMAB, OriGene offers more than 35,000 primary antibodies with extensive validation.